Summit Therapeutics Inc. Operating Expenses
Summit Therapeutics Inc. (SMMT) reported Operating Expenses of $220.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-07-23
- Summit Therapeutics Inc. operating expenses for the quarter ending 2026-06-30 was $220.50M, a 61.21% decline year-over-year.
- Summit Therapeutics Inc. operating expenses for the quarter ending 2026-03-31 was $195.21M, a 192.01% increase year-over-year.
- Summit Therapeutics Inc. operating expenses for the quarter ending 2025-12-31 was $224.93M, a 242.80% increase year-over-year.
- Summit Therapeutics Inc. operating expenses for the quarter ending 2025-09-30 was $234.21M, a 301.20% increase year-over-year.
- Summit Therapeutics Inc. operating expenses for fiscal 2025 was $1.09B, a 384.26% increase from fiscal 2024.
- Summit Therapeutics Inc. operating expenses for fiscal 2024 was $226.00M, a 62.93% decline from fiscal 2023.
- Summit Therapeutics Inc. operating expenses for fiscal 2023 was $609.65M, a 599.06% increase from fiscal 2022.
- Summit Therapeutics Inc. operating expenses for fiscal 2022 was $87.21M, a 19.96% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 11 month | Operating Expenses 11 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $220.50M 10-Q · filed 2026-07-23 | $415.71M 10-Q · filed 2026-07-23 | $640.63M derived: sum of 3 quarters · filed 2026-07-23 | $874.84M derived: sum of 4 quarters · filed 2026-07-23 | ||||||
| 2026-03-31 | $195.21M 10-Q · filed 2026-04-30 | $420.14M derived: sum of 2 quarters · filed 2026-04-30 | $654.35M derived: sum of 3 quarters · filed 2026-04-30 | $1.22B derived: sum of 4 quarters · filed 2026-07-23 | ||||||
| 2025-12-31 | $224.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $459.14M derived: sum of 2 quarters · filed 2026-02-23 | $1.03B derived: sum of 3 quarters · filed 2026-07-23 | $1.09B 10-K · filed 2026-02-23 | ||||||
| 2025-09-30 | $234.21M 10-Q · filed 2025-10-20 | $802.65M derived: sum of 2 quarters · filed 2026-07-23 | $869.50M 10-Q · filed 2025-10-20 | $935.11M derived: sum of 4 quarters · filed 2026-07-23 | ||||||
| 2025-06-30 | $568.44M 10-Q · filed 2026-07-23 | $635.29M 10-Q · filed 2026-07-23 | $700.90M derived: sum of 3 quarters · filed 2026-07-23 | $759.28M derived: sum of 4 quarters · filed 2026-07-23 | ||||||
| 2025-03-31 | $66.85M 10-Q · filed 2026-04-30 | $132.47M derived: sum of 2 quarters · filed 2026-04-30 | $190.84M derived: sum of 3 quarters · filed 2026-04-30 | $250.46M derived: sum of 4 quarters · filed 2026-04-30 | ||||||
| 2024-12-31 | $65.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $123.99M derived: sum of 2 quarters · filed 2026-02-23 | $183.61M derived: sum of 3 quarters · filed 2026-02-23 | $226.00M 10-K · filed 2026-02-23 | $226.31M 10-K · filed 2025-02-24 | |||||
| 2024-09-30 | $58.38M 10-Q · filed 2025-10-20 | $58.11M 10-Q · filed 2024-10-30 | $118.00M derived: sum of 2 quarters · filed 2025-10-20 | $160.38M 10-Q · filed 2025-10-20 | $160.49M 10-Q · filed 2024-10-30 | $195.77M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-06-30 | $59.62M 10-Q · filed 2025-08-11 | $59.78M 10-Q · filed 2024-08-06 | $102.01M 10-Q · filed 2025-08-11 | $102.38M 10-Q · filed 2024-08-06 | $137.39M derived: sum of 3 quarters · filed 2026-02-23 | $158.15M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-03-31 | $42.39M 10-Q · filed 2025-05-01 | $42.60M 10-Q · filed 2024-05-01 | $77.78M derived: sum of 2 quarters · filed 2026-02-23 | $98.53M derived: sum of 3 quarters · filed 2026-02-23 | $114.30M derived: sum of 4 quarters · filed 2026-02-23 | |||||
| 2023-12-31 | $35.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $56.15M derived: sum of 2 quarters · filed 2026-02-23 | $71.91M derived: sum of 3 quarters · filed 2026-02-23 | $609.65M 10-K · filed 2026-02-23 | $610.65M 10-K · filed 2024-02-20 | |||||
| 2023-09-30 | $20.76M 10-Q · filed 2024-10-30 | $36.52M derived: sum of 2 quarters · filed 2024-10-30 | $574.26M 10-Q · filed 2024-10-30 | $595.69M derived: sum of 4 quarters · filed 2025-02-24 | ||||||
| 2023-06-30 | $15.77M 10-Q · filed 2024-08-06 | $553.50M 10-Q · filed 2024-08-06 | $574.94M derived: sum of 3 quarters · filed 2025-02-24 | $597.56M derived: sum of 4 quarters · filed 2025-02-24 | ||||||
| 2023-03-31 | $537.74M 10-Q · filed 2024-05-01 | $559.17M derived: sum of 2 quarters · filed 2025-02-24 | $581.79M derived: sum of 3 quarters · filed 2025-02-24 | $597.73M derived: sum of 4 quarters · filed 2025-02-24 | ||||||
| 2022-12-31 | $21.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $44.05M derived: sum of 2 quarters · filed 2025-02-24 | $59.99M derived: sum of 3 quarters · filed 2025-02-24 | $87.21M 10-K · filed 2025-02-24 | ||||||
| 2022-09-30 | $22.62M 10-Q · filed 2023-11-07 | $38.56M derived: sum of 2 quarters · filed 2023-11-07 | $65.78M 10-Q · filed 2023-11-07 | $96.67M derived: sum of 4 quarters · filed 2023-11-07 | ||||||
| 2022-06-30 | $15.94M 10-Q · filed 2023-08-09 | $43.16M 10-Q · filed 2023-08-09 | $74.04M derived: sum of 3 quarters · filed 2023-08-09 | $99.65M derived: sum of 4 quarters · filed 2023-08-09 | ||||||
| 2022-03-31 | $27.21M 10-Q · filed 2023-05-11 | $58.10M derived: sum of 2 quarters · filed 2023-05-11 | $83.71M derived: sum of 3 quarters · filed 2023-05-11 | $113.61M derived: sum of 4 quarters · filed 2023-05-11 | ||||||
| 2021-12-31 | $30.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $56.49M derived: sum of 2 quarters · filed 2023-03-09 | $86.40M derived: sum of 3 quarters · filed 2023-03-09 | $108.96M 10-K · filed 2023-03-09 | ||||||
| 2021-09-30 | $25.61M 10-Q · filed 2022-11-09 | $55.51M derived: sum of 2 quarters · filed 2022-11-09 | $78.08M 10-Q · filed 2022-11-09 | $94.18M derived: sum of 4 quarters · filed 2022-12-21 | ||||||
| 2021-06-30 | $29.91M 10-Q · filed 2022-08-11 | $52.47M 10-Q · filed 2022-08-11 | $68.58M derived: sum of 3 quarters · filed 2022-12-21 | $90.01M derived: sum of 4 quarters · filed 2022-12-21 | ||||||
| 2021-03-31 | $22.56M 10-Q · filed 2022-05-11 | $38.67M derived: sum of 2 quarters · filed 2022-12-21 | $60.10M derived: sum of 3 quarters · filed 2022-12-21 | $79.44M derived: sum of 4 quarters · filed 2022-12-21 | ||||||
| 2020-12-31 | $16.10M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | $37.53M derived: sum of 2 quarters · filed 2022-12-21 | $56.88M derived: sum of 3 quarters · filed 2022-12-21 | $73.36M 10-K/A · filed 2022-12-21 | ||||||
| 2020-09-30 | $21.43M 10-Q · filed 2021-11-15 | $22.71M 10-Q · filed 2020-11-16 | $40.78M derived: sum of 2 quarters · filed 2021-11-15 | $57.26M 10-Q · filed 2021-11-15 | $55.27M 10-Q · filed 2020-11-16 | |||||
| 2020-06-30 | $19.35M 10-Q · filed 2021-08-12 | $19.40M 8-K · filed 2020-09-29 | $35.83M 10-Q · filed 2021-08-12 | $32.56M 8-K · filed 2020-09-29 | ||||||
| 2020-03-31 | $16.48M 10-Q · filed 2021-05-17 | |||||||||
| 2019-12-31 | $51.09M 10-K · filed 2021-03-31 | $52.42M 8-K · filed 2020-09-29 | ||||||||
| 2019-09-30 | $12.63M 10-Q · filed 2020-11-16 | $26.03M derived: sum of 2 quarters · filed 2020-11-16 | $40.50M 10-Q · filed 2020-11-16 | |||||||
| 2019-06-30 | $13.39M 8-K · filed 2020-09-29 | $27.87M 8-K · filed 2020-09-29 | ||||||||
| 2019-01-31 | $74.31M 10-K · filed 2021-03-31 | $73.69M 8-K · filed 2020-09-29 | ||||||||
| 2018-01-31 | $53.38M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |